NOW Trial: Neoadjuvant PARPi with Shannon Westin

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Shannon Westin to discuss the NOW trial. Dr. Westin is Professor and Center Medical Director in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas. She is the co-director of the Ovarian Cancer Moon Shot and Director of Early Drug Development. Highlights: Olaparib was feasible and safe as a neoadjuvant strategy in germline mutant advanced ovarian cancer. Surgical outcomes were outstanding after only twocycles of neoadjuvant olaparib therapy. Adverse events were as expected for PARP inhibition. The NOW trial provides proof of concept for targeted therapy in lieu of chemotherapy for neoadjuvant treatment of ovarian cancer.